HQ
  • About A*STAR
    • Corporate Profile
      • A*STAR Board Members
      • Senior Management
      • Organisation Structure
      • Corporate Social Responsibility
      • Diversity at A*STAR
      • A*STAR Sustainability
    • Annual Report
    • A*STAR Global Network
  • Research
    • About A*STAR Research
    • Funding Opportunities
    • S-SEAF
    • Research Ethics
    • Biomedical Research Council
    • Science and Engineering Research Council
    • Our People
      • Highly Cited Researchers
      • Honours and Accolades
  • Innovation & Enterprise
    • About I&E
    • Innovation Offerings
  • Scholarships
  • News
    • A*STAR News
      • Publicity Highlights
      • Press Releases
      • Features
      • Committee Of Supply (COS) Debate
    • Case Studies
    • Faces of A*STAR
    • National Survey of RIE
    • Connect with Us
  • Career
  • Home
  • News
  • A*STAR News
  • Publicity Highlights
  • A*STAR News
    • Publicity Highlights
    • Press Releases
    • Features
    • Committee Of Supply (COS) Debate
  • Case Studies
  • Faces of A*STAR
  • National Survey of RIE
  • Connect with Us
Agency for Science, Technology and Research (A*STAR)
PartnershipsCareersSuppliersContact UsWhistleblowing
  • Report Vulnerability
  • Privacy Statement
  • Terms & Conditions
    • Publicity Highlights

    National platform launch to boost Singapore’s drug development efforts

    26 Jun 2019
    • Whatsapp
    • Telegram
    • Facebook
    • Twitter
    • Email
    • Linked In

    Collaboration key to creating greater value for biomedical ecosystem

    On 26 June- Mr Heng Swee Keat- Deputy Prime Minister and Minister for Finance- and Chairman of the National Research Foundation (NRF) officially opened the Experimental Drug Development Centre (EDDC)- a national platform for drug discovery and development to channel high potential drug candidates toward commercial and clinical outcomes. The new centre integrates A*STAR’s Experimental Therapeutics Centre (ETC)- the Drug- Discovery and Development (D3) unit- and the Experimental Biotherapeutics Centre (EBC) and will build on the combined capabilities we have developed over the years to support our partners in efforts to discover and develop innovative medicines.

    DPM Heng also announced the launch of the Target Translation Consortium (TTC)- to facilitate early-stage drug discovery efforts across public sector institutions. The consortium brings together A*STAR- Duke-NUS Medical School (Duke-NUS)- Lee Kong Chian School of Medicine- NTU (LKCMedicine)- Nanyang Technological University (NTU)- National Healthcare Group (NHG)- National University of Singapore (NUS)- National University Health System (NUHS)- and SingHealth.

    In addition- the new Singapore Therapeutics Development Review (STDR) grant scheme was launched- consolidating three separate schemes by A*STAR- National Health Innovation Centre Singapore (NHIC)- and Singapore-MIT Alliance for Research and Technology (SMART) into a new grant that funds early-stage projects.

    These partnerships will facilitate collaboration in an increasingly sophisticated drug discovery and development space.

    Related TopicsEDDC